Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing

WEDNESDAY, Oct. 4, 2023 (HealthDay News) -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Related Posts
Las terapias que pueden ayudar a aliviar la falta de aliento y la fatiga de la COVID prolongada
LUNES, 22 de mayo de 2022 (HealthDay News) -- La terapia ocupacional o el...
No Change Seen in Limited Access to Mammography From 2006 to 2022
TUESDAY, Dec. 20, 2022 (HealthDay News) -- The proportion of U.S. women with...
Don’t Use Certain Tests for Pregnancy, Ovulation, UTIs, FDA Warns
MONDAY, Aug. 14, 2023 (HealthDay News) – The U.S. Food and Drug Administration...
FDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants
MONDAY, Dec. 5, 2022 (HealthDay News) -- The last of six COVID-19 monoclonal...